CN115154502B - Anti-inflammatory composition and preparation method and application thereof - Google Patents

Anti-inflammatory composition and preparation method and application thereof Download PDF

Info

Publication number
CN115154502B
CN115154502B CN202210924743.2A CN202210924743A CN115154502B CN 115154502 B CN115154502 B CN 115154502B CN 202210924743 A CN202210924743 A CN 202210924743A CN 115154502 B CN115154502 B CN 115154502B
Authority
CN
China
Prior art keywords
extract
vitamin
parts
inflammatory composition
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210924743.2A
Other languages
Chinese (zh)
Other versions
CN115154502A (en
Inventor
张洁
韩宝翠
王小宇
刘振涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heilongjiang Wusuli River Pharmaceutical Co ltd
Original Assignee
Heilongjiang Wusuli River Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heilongjiang Wusuli River Pharmaceutical Co ltd filed Critical Heilongjiang Wusuli River Pharmaceutical Co ltd
Priority to CN202210924743.2A priority Critical patent/CN115154502B/en
Publication of CN115154502A publication Critical patent/CN115154502A/en
Application granted granted Critical
Publication of CN115154502B publication Critical patent/CN115154502B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides an anti-inflammatory composition, a preparation method and application thereof, wherein the anti-inflammatory composition comprises, by weight, 100-140 parts of asiatic moonseed rhizome extract, 50-70 parts of acanthopanax leaf extract and 0.5-1.5 parts of vitamin A. The anti-inflammatory composition provided by the invention can effectively eliminate inflammation, has the effects of diminishing inflammation and easing pain, and can effectively treat pharyngitis and related diseases.

Description

Anti-inflammatory composition and preparation method and application thereof
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to an anti-inflammatory composition and a preparation method and application thereof, in particular to an anti-inflammatory composition with anti-inflammatory and analgesic effects and a preparation method and application thereof.
Background
Pharyngitis is nonspecific inflammation of pharynx, is a common name for inflammation caused by infection of pharynx with various microorganisms, and can be classified into acute pharyngitis and chronic pharyngitis, mainly viral and bacterial infections, and is usually infected by spray or direct contact. Patients often present with symptoms of dry throat, hypoxia, pharyngalgia, dysphagia, etc., which seriously affect normal life.
CN104606546a discloses a traditional Chinese medicine composition for treating chronic pharyngitis and a preparation method thereof, wherein the traditional Chinese medicine composition for treating chronic pharyngitis comprises reed rhizome, chinese olive, liquorice, chrysanthemum, radix scrophulariae, white mustard seed, buttercup, fructus terminaliae Billeyanae and jazz. The preparation method comprises the following steps: respectively taking 8-14 parts of dry reed rhizome, 4-10 parts of olive, 5-11 parts of liquorice, 4-9 parts of chrysanthemum, 6-12 parts of radix scrophulariae, 5-9 parts of white mustard seed, 4-9 parts of ranunculus, 4-8 parts of fructus terminalia bellerica and 2-6 parts of jujuba, respectively mashing the above traditional Chinese medicines, grinding the mashed traditional Chinese medicines to obtain powder, and uniformly mixing the powder to obtain the traditional Chinese medicine composition for treating chronic pharyngitis, which has the advantages of quick response, good curative effect and no toxic or side effect.
CN111450211a discloses a tablet for treating pharyngitis and its preparation method, the raw materials of the tablet comprise radix scrophulariae, radix Stemonae (prepared), radix asparagi, cortex moutan, radix Ophiopogonis, flos Farfarae (prepared), semen Oroxyli, rehmanniae radix, radix Isatidis, periostracum Cicadae, fructus Canarii albi, peppermint oil, sucrose, dextrin and magnesium stearate, the tablet is a tablet, the outside of the tablet is provided with a coating layer, the components of the coating layer comprise extract powder of the tablet, sucrose powder, dextrin, 95% ethanol, peppermint oil and cyclodextrin and substance and magnesium stearate, and the tablet is prepared by pulverizing, sieving, dosing, granulating, drying, granulating, total mixing, tabletting and coating and packaging processes sequentially. The pharyngitis tablet provided by the invention has good effects of nourishing yin and moistening lung, clearing heat and detoxicating, clearing heat and relieving sore throat and cough and itching.
Because pharyngitis seriously affects normal life of people, how to provide a medicine capable of effectively treating pharyngitis becomes a problem to be solved.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide an anti-inflammatory composition, a preparation method and application thereof, in particular to an anti-inflammatory composition with anti-inflammatory and analgesic effects, and a preparation method and application thereof. The anti-inflammatory composition provided by the invention can effectively eliminate inflammation, has the effects of diminishing inflammation and easing pain, and can effectively treat pharyngitis and related diseases.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the present invention provides an anti-inflammatory composition comprising, in parts by weight, 100-140 parts of asiatic moonseed rhizome extract, 50-70 parts of acanthopanax leaf extract, and 0.5-1.5 parts of vitamin a.
The parts of the asiatic moonseed rhizome extract may be 100 parts, 110 parts, 120 parts, 130 parts or 140 parts, the parts of the acanthopanax leaf extract may be 50 parts, 55 parts, 60 parts, 65 parts or 70 parts, and the parts of the vitamin a may be 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 parts, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts or 1.5 parts, etc., but the present invention is not limited to the above-listed values, and other non-listed values within the above-listed values are equally applicable.
The invention adopts the combination of the asiatic moonseed rhizome extract, the acanthopanax leaf extract and the vitamin A, and the synergistic effect can effectively inhibit inflammatory symptoms, has the effects of diminishing inflammation and easing pain, and can effectively treat pharyngitis and related diseases.
Preferably, the anti-inflammatory composition comprises 110-130 parts by weight of asiatic moonseed rhizome extract, 55-65 parts by weight of acanthopanax leaf extract and 0.7-1.3 parts by weight of vitamin A.
Preferably, the asiatic moonseed rhizome extract is prepared by a method comprising the following steps:
pulverizing rhizoma Menispermi, mixing with acid solution, ultrasonic treating, centrifuging to obtain supernatant, adjusting pH, standing for precipitation, filtering to obtain precipitate, washing with water, and drying to obtain rhizoma Menispermi extract.
Preferably, the acid includes any one or a combination of at least two of sulfuric acid, nitric acid or hydrochloric acid, for example, a combination of sulfuric acid and nitric acid, a combination of sulfuric acid and hydrochloric acid, a combination of hydrochloric acid and nitric acid, or the like, but is not limited to the above-listed combinations, and other non-listed combinations within the above-listed combinations are equally applicable, and combinations of sulfuric acid and nitric acid are preferred.
Preferably, the mass fraction of the acid solution is 0.5-10%.
Preferably, the ratio of the rhizoma Menispermi to the acid solution is 1 (6-10) g/mL.
Preferably, the ultrasound is carried out at a temperature of 55-65 ℃.
Preferably, the number of times of ultrasonic waves is at least 3, and the time of single ultrasonic waves is 35-45min.
Preferably, the pH is adjusted to a pH of 9-10.
The mass fraction of the acid solution may be 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%, the ratio of rhizoma Menispermi to the acid solution may be 1:6g/mL, 1:7g/mL, 1:8g/mL, 1:9g/mL or 1:10g/mL, the temperature may be 55 ℃, 56 ℃, 57 ℃, 58 ℃, 59 ℃, 60 ℃, 61 ℃, 62 ℃, 63 ℃, 64 ℃, 65 ℃ or the like, the number of times of ultrasound may be 3, 4, or 5, etc., the time of a single ultrasound may be 35min, 36min, 37min, 38min, 39min, 40min, 41min, 42min, 43min, 44min, 45min, etc., the pH may be 9, 9.2, 9.4, 9.6, 9.8, or 10, etc., but is not limited to the above-mentioned values, and other values not mentioned in the above numerical ranges are equally applicable.
Preferably, the acanthopanax leaf extract is prepared by a method comprising the following steps:
pulverizing folium Acanthopanacis Senticosi, mixing with ethanol solution, ultrasound, centrifuging to obtain supernatant, adding acid solution to adjust pH, standing for precipitation, filtering to obtain precipitate, washing with water, and drying to obtain folium Acanthopanacis Senticosi extract.
Preferably, the alcohol solution comprises an aqueous ethanol solution, and the volume fraction of the aqueous ethanol solution is 75-85%.
Preferably, the ratio of the acanthopanax leaves to the alcohol solution is 1 (8-12) g/mL.
Preferably, the ultrasound is carried out at a temperature of 55-65 ℃.
Preferably, the time of the ultrasonic treatment is 35-45min.
Preferably, the pH is adjusted to 4-5.
The volume fraction of the aqueous ethanol solution may be 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, etc., the ratio of the acanthopanax leaf to the alcoholic solution may be 1:8g/mL, 1:9g/mL, 1:10g/mL, 1:11g/mL, or 1:12g/mL, etc., the temperature may be 55 ℃, 56 ℃, 57 ℃, 58 ℃, 59 ℃, 60 ℃, 61 ℃, 62 ℃, 63 ℃, 64 ℃, 65 ℃ or the like, the time of the ultrasound may be 35min, 36min, 37min, 38min, 39min, 40min, 41min, 42min, 43min, 44min, 45min, etc., and the pH may be adjusted to 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5, etc., but the invention is not limited to the above-listed values, and other values not listed in the above range may be equally applicable.
In a second aspect, the present invention provides a method of preparing an anti-inflammatory composition as described above, the method comprising the steps of:
dissolving vitamin A with ethanol, mixing with cyclodextrin saturated water solution, stirring, standing, filtering, drying to obtain vitamin A clathrate, and mixing with rhizoma Menispermi extract and radix Acanthopanacis Senticosi leaf extract to obtain the antiinflammatory composition.
Preferably, the mass ratio of the vitamin A to the cyclodextrin is (2-4): 1.
Preferably, the mixing is carried out at a temperature of 55-65 ℃.
Preferably, the stirring time is 1.5-2.5 hours.
Preferably, the time of the standing is 8-16 hours.
The mass ratio of vitamin A to cyclodextrin may be 2:1, 2.5:1, 3:1, 3.5:1 or 4:1, the temperature may be 55 ℃, 56 ℃, 57 ℃, 58 ℃, 59 ℃, 60 ℃, 61 ℃, 62 ℃, 63 ℃, 64 ℃ or 65 ℃, the stirring time may be 1.5h, 1.7h, 1.9h, 2.1h, 2.3h or 2.5h, the standing time may be 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h or 16h, etc., but the method is not limited to the above-mentioned values, and other non-mentioned values in the above-mentioned value range are applicable.
In a third aspect, the invention also provides application of the anti-inflammatory composition in preparing an anti-tonsillitis and anti-pharyngitis medicament.
Compared with the prior art, the invention has the following beneficial effects:
the invention provides an anti-inflammatory composition, which is prepared by compounding rhizoma Menispermi extract, radix Acanthopanacis Senticosi leaf extract and vitamin A, and has synergistic effect, can effectively inhibit inflammatory symptoms, has anti-inflammatory and analgesic effects, and can effectively treat pharyngitis and related diseases.
Detailed Description
In order to further describe the technical means adopted by the present invention and the effects thereof, the following describes the technical scheme of the present invention in combination with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
Preparation example 1
The preparation example provides a rhizoma Menispermi extract, which is prepared by the following steps:
pulverizing rhizoma Menispermi, mixing with 0.5% nitric acid and sulfuric acid solution (feed liquid ratio 1:8g/mL, sulfuric acid and nitric acid volume ratio 1:1) at 60deg.C for three times (40 min each time), centrifuging at 4000r/min for 5min each time, collecting supernatant, mixing the three supernatants, adjusting pH to 9.5 with sodium carbonate solution, standing for precipitation, filtering, washing the precipitate to neutrality, and drying at 55deg.C to obtain rhizoma Menispermi extract.
Preparation example 2
The preparation example provides an acanthopanax leaf extract, and the preparation method comprises the following steps:
drying and pulverizing radix Acanthopanacis Senticosi leaves into powder, soaking in 80% ethanol water solution at a ratio of 1:10 for 2 hr, ultrasonic extracting at 60deg.C for 40min, centrifuging at 4000r/min for 5min to obtain supernatant, adding 10% hydrochloric acid solution to adjust pH to 4.5, standing, removing supernatant after precipitation, filtering, washing with water to neutrality, drying at 55deg.C, and pulverizing into fine powder to obtain radix Acanthopanacis Senticosi leaf extract.
Preparation example 3
The preparation example provides a vitamin A inclusion compound, and the preparation method comprises the following steps:
dissolving vitamin A in proper amount of ethanol, adding the mixture into beta-cyclodextrin saturated aqueous solution at 60 ℃ (the mass ratio of the vitamin A to the beta-cyclodextrin is 3:1), continuously stirring, cooling to 25 ℃ after 2 hours, standing for 12 hours, filtering and drying to obtain the vitamin A inclusion compound.
Preparation example 4
The preparation example provides a rhizoma Menispermi extract, and the preparation method is the same as that of preparation example 1 except that nitric acid is replaced by sulfuric acid with the same amount.
Preparation example 5
The preparation example provides a rhizoma Menispermi extract, and the preparation method is the same as that of preparation example 1 except that sulfuric acid is replaced by equivalent nitric acid.
Preparation example 6
The preparation example provides a rhizoma Menispermi extract, and the preparation method is the same as that of preparation example 1 except that nitric acid is replaced by hydrochloric acid with the same amount.
Preparation example 7
The preparation example provides an acanthopanax leaf extract, and the preparation method is the same as that of preparation example 2 except that the volume fraction of the ethanol aqueous solution is 70%.
Preparation example 8
The preparation example provides an acanthopanax leaf extract, and the preparation method is the same as that of preparation example 2 except that the volume fraction of the ethanol aqueous solution is 90%.
Example 1
The present example provides an anti-inflammatory composition, prepared as follows:
mixing rhizoma Menispermi extract provided in preparation example 1, folium Acanthopanacis Senticosi extract provided in preparation example 2 and vitamin A clathrate provided in preparation example 3 (mass ratio of rhizoma Menispermi extract, folium Acanthopanacis Senticosi extract and vitamin A is 120:60:1), and sieving with 80 mesh sieve to obtain the antiinflammatory composition.
Example 2
The present example provides an anti-inflammatory composition, prepared as follows:
mixing rhizoma Menispermi extract provided in preparation example 1, folium Acanthopanacis Senticosi extract provided in preparation example 2 and vitamin A clathrate provided in preparation example 3 (mass ratio of rhizoma Menispermi extract, folium Acanthopanacis Senticosi extract and vitamin A is 110:65:0.7), and sieving with 80 mesh sieve to obtain the antiinflammatory composition.
Example 3
The present example provides an anti-inflammatory composition, prepared as follows:
mixing rhizoma Menispermi extract (obtained from Lin Bao pharmaceutical industry Co., ltd.) with radix Acanthopanacis Senticosi leaf extract (obtained from Canton Jiali Biotechnology Co., ltd.) and vitamin A clathrate prepared in preparation example 3 (mass ratio of rhizoma Menispermi extract, radix Acanthopanacis Senticosi leaf extract and vitamin A is 130:55:1.3), and sieving with 80 mesh sieve to obtain the antiinflammatory composition.
Example 4
The present example provides an anti-inflammatory composition, prepared as follows:
mixing rhizoma Menispermi extract provided in preparation example 1, folium Acanthopanacis Senticosi extract provided in preparation example 2 and vitamin A clathrate provided in preparation example 3 (mass ratio of rhizoma Menispermi extract, folium Acanthopanacis Senticosi extract and vitamin A is 100:70:0.5), and sieving with 80 mesh sieve to obtain the antiinflammatory composition.
Example 5
The present example provides an anti-inflammatory composition, prepared as follows:
mixing rhizoma Menispermi extract provided in preparation example 1, folium Acanthopanacis Senticosi extract provided in preparation example 2 and vitamin A clathrate provided in preparation example 3 (mass ratio of rhizoma Menispermi extract, folium Acanthopanacis Senticosi extract and vitamin A is 140:50:1.5), and sieving with 80 mesh sieve to obtain the antiinflammatory composition.
Examples 6 to 8
Examples 6-8 provide an anti-inflammatory composition, respectively, and the preparation method is the same as example 1 except that the rhizoma Menispermi extract provided in preparation example 1 is replaced with the rhizoma Menispermi extract provided in preparation examples 4-6, respectively.
Examples 9 to 10
Examples 9 to 10 respectively provide an anti-inflammatory composition, and the preparation method is the same as example 1 except that the extract of acanthopanax leaf provided in preparation example 2 is replaced with the extract of acanthopanax leaf provided in preparation examples 7 to 8 respectively.
Comparative example 1
This comparative example provides an anti-inflammatory composition prepared in the same manner as in example 1 except that no asiatic moonseed extract was added and a reduced fraction was allocated to acanthopanax leaf extract.
Comparative example 2
This comparative example provides an anti-inflammatory composition prepared in the same manner as in example 1 except that the extract of acanthopanax leaf was not added and the distribution of the extract of asiatic moonseed rhizome was reduced.
Comparative example 3
This comparative example provides an anti-inflammatory composition prepared in the same manner as in example 1 except that no vitamin A clathrate was added and the reduced portion of vitamin A was proportionally distributed to the acanthopanax leaf extract and the asiatic moonseed rhizome extract.
And (3) verifying anti-inflammatory effect:
65 SD rats were collected and equally divided into 13 groups of 5 rats, and the rats were aseptically anesthetized with diethyl ether and subcutaneously injected with 2mL of a 2% agar physiological saline solution into the dorsal midline of the rats. Starting administration on day 2 of operation (each group was prepared by using the anti-inflammatory compositions provided in examples 1 to 10 and comparative examples 1 to 3), 1.364mg/kg was infused per day, 1 time per day, 15 days were continued, rats were sacrificed after 1 hour of last administration on day 15, back granulation agar blocks were peeled off, blotted with filter paper, weighed on a glass with an analytical balance, the granulation wet mass was recorded, dried in an oven at 60 ℃ for 12 hours, and then weighed, and the weight of cotton balls was subtracted to obtain the granulation weight. The average of the granulation weights for each group was recorded and calculated as follows:
the data show that the anti-inflammatory composition provided by the invention can effectively reduce the weight of granulation and relieve inflammation symptoms; as can be seen from comparative examples 1 to 5, the present invention can further improve the anti-inflammatory effect of the product by controlling the respective raw material ratios; comparing examples 1, 6-8, it can be found that the invention can further improve the extraction effect of rhizoma Menispermi by adopting specific acid solution combination, thereby improving the anti-inflammatory effect of the product; comparing examples 1 and 9-10, the invention can effectively extract the active ingredients in the acanthopanax leaves by controlling the volume fraction of the ethanol aqueous solution, thereby improving the anti-inflammatory effect of the product; as can be seen from comparative example 1 and comparative examples 1 to 3, the present invention can effectively inhibit inflammatory symptoms and reduce the weight of granulation by adopting the combination of rhizoma Menispermi extract, radix Acanthopanacis Senticosi leaf extract and vitamin A.
Pharyngitis treatment test:
100 Japanese white rabbits are subjected to a pharyngitis experimental model, 2.5% ammonia water is sprayed on the throat of the rabbits by a throat sprayer at 1-20 am, 25% turpentine oil is respectively injected under mucous membranes on the left side and the right side of the throat of the rabbits by a tonsil injection needle at 11 am, and after the animals are killed by injecting an air plug in 21 st day, the mucous membrane of the throat and a pharyngeal tissue are immediately taken down to be cut into slices, so that whether molding is successful is determined. Taking 65 rabbits with successful molding, randomly dividing the rabbits into 13 groups, 5 in each group, namely the groups 1-10 and the groups 1-3 in each example, starting administration (each group adopts the anti-inflammatory composition provided by the examples 1-10 and the comparative examples 1-3), filling 1.364mg/kg each day for 1 time, continuously administering for 15 days, after the last administration, taking pharyngeal tissues for fixing in 10% formaldehyde solution immediately after the intracardiac injection air lock of the experimental rabbits is killed, observing the structures of the rabbits under an optical microscope and an electron microscope, and counting the number of the rabbits with abnormal phenomena, wherein the results (-representing that no occurrence, + represents occurrence) are as follows:
the anti-inflammatory composition provided by the invention can be found to be capable of effectively reducing the generation of inflammatory symptoms and effectively treating pharyngitis; as can be seen from comparative examples 1 to 5, the present invention can further improve the anti-pharyngitis effect of the product by controlling the ratios of the raw materials; comparing examples 1 and 6-8, the invention can further improve the extraction effect of rhizoma Menispermi by adopting the specific acid solution combination, thereby improving the effect of the product in treating pharyngitis; comparing examples 1 and 9-10, the invention can effectively extract the active ingredients in the acanthopanax leaves by controlling the volume fraction of the ethanol aqueous solution, thereby improving the effect of the product on treating pharyngitis; as can be seen from comparative example 1 and comparative examples 1 to 3, the invention can effectively reduce the generation of inflammatory symptoms and effectively treat pharyngitis by adopting the combination of the asiatic moonseed rhizome extract, the acanthopanax leaf extract and the vitamin A.
And (3) analgesic effect test:
65 mice were randomly divided into 13 groups of 5 mice each, examples 1 to 10 and comparative examples 1 to 3, respectively, and administration was started (each group was prepared using the anti-inflammatory compositions provided in examples 1 to 10 and comparative examples 1 to 3), 1.364mg/kg was administered by stomach irrigation daily, 1 time a day, and 7 days after the last administration, 0.6% hac 0.1ml was intraperitoneally injected into each group of mice, and the number of twists of mice in 15 minutes was observed, and the average value was calculated as follows:
group of Number of times of twisting body Group of Number of times of twisting body Group of Number of times of twisting body
Example 1 4.8 Example 6 7.1 Comparative example 1 11.6
Example 2 6.5 Example 7 7.4 Comparative example 2 13.2
Example 3 6.2 Example 8 6.8 Comparative example 3 11.3
Example 4 7.1 Example 9 7.1
Example 5 7.3 Example 10 7.3
The anti-inflammatory composition provided by the invention can be found to be capable of effectively relieving pain symptoms and reducing the number of times of twisting the body of a mouse; comparing examples 1-5, it can be found that the invention can further improve the analgesic effect of the product by controlling the ratios of the raw materials; comparing examples 1 and 6-8, it can be found that the invention can further improve the extraction effect of rhizoma Menispermi by adopting specific acid solution combination, thereby improving the analgesic effect of the product; comparing examples 1 and 9-10, the invention can effectively extract the active ingredients in the acanthopanax leaves by controlling the volume fraction of the ethanol aqueous solution, thereby improving the analgesic effect of the product; as can be seen from comparative example 1 and comparative examples 1 to 3, the invention can effectively relieve pain symptoms and reduce the number of times of twisting body of mice by adopting the combination of rhizoma Menispermi extract, radix Acanthopanacis Senticosi leaf extract and vitamin A.
The applicant states that the invention is illustrated by the above examples as well as methods of making and using the same, but the invention is not limited to, i.e., does not necessarily rely on, the above examples to practice the invention. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.

Claims (8)

1. An anti-inflammatory composition is characterized by comprising, by weight, 100-140 parts of asiatic moonseed rhizome extract, 50-70 parts of acanthopanax leaf extract and 0.5-1.5 parts of vitamin A;
the rhizoma Menispermi extract is prepared by a method comprising the following steps:
pulverizing rhizoma Menispermi, mixing with acid solution, performing ultrasonic treatment, centrifuging to obtain supernatant, adjusting pH, standing for precipitation, filtering to obtain precipitate, washing with water, and drying to obtain rhizoma Menispermi extract;
the acanthopanax leaf extract is prepared by a method comprising the following steps:
pulverizing folium Acanthopanacis Senticosi, mixing with ethanol solution, ultrasound, centrifuging to obtain supernatant, adding acid solution to adjust pH, standing for precipitation, filtering to obtain precipitate, washing with water, and drying to obtain folium Acanthopanacis Senticosi extract;
the vitamin A is used in the form of a vitamin A inclusion compound, and the vitamin A inclusion compound is prepared by a method comprising the following steps:
dissolving vitamin A with ethanol, mixing with cyclodextrin saturated water solution, stirring, standing, filtering, and drying to obtain vitamin A clathrate.
2. The anti-inflammatory composition according to claim 1, wherein the anti-inflammatory composition is prepared from 110 to 130 parts by weight of asiatic moonseed rhizome extract, 55 to 65 parts by weight of acanthopanax leaf extract, and 0.7 to 1.3 parts by weight of vitamin a.
3. The anti-inflammatory composition according to claim 1, wherein the acid is any one or a combination of two of sulfuric acid, nitric acid, and hydrochloric acid in the process for producing the asiatic moonseed rhizome extract;
the mass fraction of the acid solution is 0.5-10%;
the ratio of the rhizoma Menispermi to the acid solution is 1 (6-10) g/mL;
the ultrasonic treatment is carried out at a temperature of 55-65 ℃;
the times of the ultrasonic waves are at least 3 times, and the time of single ultrasonic waves is 35-45 min;
the pH is adjusted to 9-10.
4. The anti-inflammatory composition of claim 3 wherein the acid is a combination of sulfuric acid and nitric acid.
5. The anti-inflammatory composition according to claim 1, wherein in the preparation method of the acanthopanax leaf extract, the alcohol solution comprises an aqueous ethanol solution, and the volume fraction of the aqueous ethanol solution is 75-85%;
the feed liquid ratio of the acanthopanax leaves to the alcohol solution is 1 (8-12) g/mL;
the ultrasonic treatment is carried out at a temperature of 55-65 ℃;
the ultrasonic time is 35-45 min;
the pH is adjusted to 4-5.
6. A method of preparing an anti-inflammatory composition according to any one of claims 1 to 5, comprising the steps of:
dissolving vitamin A with ethanol, mixing with cyclodextrin saturated water solution, stirring, standing, filtering, drying to obtain vitamin A clathrate, and mixing with rhizoma Menispermi extract and radix Acanthopanacis Senticosi leaf extract to obtain the antiinflammatory composition.
7. The method according to claim 6, wherein the mass ratio of vitamin A to cyclodextrin is (2-4): 1;
the mixing is carried out at a temperature of 55-65 ℃;
the stirring time is 1.5-2.5 h;
the standing time is 8-16h.
8. Use of an anti-inflammatory composition according to any one of claims 1-5 in the manufacture of an anti-pharyngitis medicament.
CN202210924743.2A 2022-08-02 2022-08-02 Anti-inflammatory composition and preparation method and application thereof Active CN115154502B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210924743.2A CN115154502B (en) 2022-08-02 2022-08-02 Anti-inflammatory composition and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210924743.2A CN115154502B (en) 2022-08-02 2022-08-02 Anti-inflammatory composition and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN115154502A CN115154502A (en) 2022-10-11
CN115154502B true CN115154502B (en) 2023-11-03

Family

ID=83477918

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210924743.2A Active CN115154502B (en) 2022-08-02 2022-08-02 Anti-inflammatory composition and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN115154502B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101239168A (en) * 2008-01-11 2008-08-13 王玉亮 Composition with ease pain anti-inflammatory action
KR20080101341A (en) * 2007-05-17 2008-11-21 건국대학교 산학협력단 Composition for the anti-inflammatory and analgesia comprising tannin-contained actinidia polygama extract
CN101795693A (en) * 2007-09-04 2010-08-04 宝洁公司 Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol
KR20180036024A (en) * 2016-09-30 2018-04-09 코웨이 주식회사 A composition comprising Sauropus spatulifolius Beille extracts having anti-inflammation activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080101341A (en) * 2007-05-17 2008-11-21 건국대학교 산학협력단 Composition for the anti-inflammatory and analgesia comprising tannin-contained actinidia polygama extract
CN101795693A (en) * 2007-09-04 2010-08-04 宝洁公司 Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol
CN101239168A (en) * 2008-01-11 2008-08-13 王玉亮 Composition with ease pain anti-inflammatory action
KR20180036024A (en) * 2016-09-30 2018-04-09 코웨이 주식회사 A composition comprising Sauropus spatulifolius Beille extracts having anti-inflammation activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
复方北豆根氨酚那敏片质量标准研究;董俊;冉维;杨允波;杨勇;;现代医药卫生;-;第-卷(第12期);第1765-1767，1771页 *

Also Published As

Publication number Publication date
CN115154502A (en) 2022-10-11

Similar Documents

Publication Publication Date Title
CN106668832B (en) Application of polypeptide in preparation of medicine for treating enterovirus infection
CN103202880B (en) Medicine for treating allergic rhinitis and method for preparing medicine
CN101049424A (en) Medication for treating infection in respiratory system
CN101040950A (en) Method of preparing Ynxingchao dropping pills compound
CN101152509A (en) Method of preparing traditional Chinese medicine preparation for treating chronic pharyngitis
CN115154502B (en) Anti-inflammatory composition and preparation method and application thereof
CN1234342C (en) Chinese medicinal tooth-paste
CN111249401A (en) Traditional Chinese medicine spray for treating and relieving postoperative thirst and xerostomia and preparation method
CN104800268A (en) Compound taraxacum mongolicum and andrographis paniculata lozenge for treating laryngopharyngitis and amygdalitis as well as preparation method thereof
CN116115689A (en) Seven-orifice rhinitis-relieving spray and preparation method thereof
CN103656291B (en) Medicine for treating pharyngitis and preparation method thereof
CN1278709C (en) Medicine for treating cold and its preparing process
CN113425782A (en) Preparation method of mussaenda pubescens heat clearing preparation
CN113616721A (en) Pharmaceutical composition for treating oral ulcer and preparation method and application thereof
CN102755428B (en) Calculus bovis yijin tablet for treating chronic pharyngitis and preparation method thereof
CN112386629A (en) Spray for treating rhinitis and relieving cold symptoms and preparation method thereof
CN109125703A (en) A kind of pharmaceutical composition and preparation method thereof for treating vaginitis
CN110604759A (en) Rhinitis spray and preparation method thereof
CN103735970A (en) Malong cough relieving granule and preparation method thereof
CN1397329A (en) Medicine for treating acne and its preparing process
CN109999046B (en) Poria cocos oligosaccharide and preparation method and application thereof
CN115814037B (en) Traditional Chinese medicine composition for treating gastric ulcer and preparation method thereof
CN109820826B (en) Anti-inflammatory traditional Chinese medicine granules and preparation method thereof
CN101569714A (en) Traditional Chinese medicine compound for treating chronic pharyngitis and the preparation method thereof
CN1406611A (en) Medicine for cough and preparation thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant